Midodrine and clonidine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot Study

American Journal of Gastroenterology

Volumn 108, Issue 4, 2013, Pages 560-567

  Singh, Virendra ^a   Singh, Ajay ^a   Singh, Baljinder ^a   Vijayvergiya, Rajesh ^a   Sharma, Navneet ^a   Ghai, Anchal ^a   Bhalla, Ashish ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CLONIDINE; MIDODRINE; RENIN; SODIUM;

ABDOMINAL PAIN; ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; ASCITES; BACTERIAL PERITONITIS; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEADACHE; HEART OUTPUT; HEMODYNAMICS; HEPATORENAL SYNDROME; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MODEL FOR END STAGE LIVER DISEASE SCORE; MORTALITY; OUTCOME ASSESSMENT; PILOT STUDY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SEPSIS; SODIUM URINE LEVEL; SYSTEMIC VASCULAR RESISTANCE; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; URINE VOLUME; XEROSTOMIA;

ADRENERGIC ALPHA-1 RECEPTOR AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADULT; AGED; ASCITES; CLONIDINE; DRUG THERAPY, COMBINATION; FEMALE; HEMODYNAMICS; HUMANS; KIDNEY; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MIDODRINE; PILOT PROJECTS; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME;

EID: 84875958301     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.9     Document Type: Article

References (36)

1. Bories P, Garcia-Compean D, Michel H et al. The treatment of refractory ascites by the LeVeen shunt:a multi centre controlled trial (57 patients). J Hepatol 1986; 3: 212-8.
2. Gine's P, Angeli P, Lenz K et al. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010; 53: 397-417.
3. Schrier RW, Arroyo V, Bernardi M et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.
4. Gines P, Cardeenas A, Arroyo V et al. Management of cirrhosis and ascites. N Engl Med 2004; 350: 1646-54.
5. Cardenas A, Arroyo V. Mechanism of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinal Metab 2003; 17: 607-22.
6. Arroyo V, Planas R, Gaya J et al. Sympathetic nervous activity, reninangiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water retention. Eur J Clin Invest 1983; 13: 271-8.
7. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002; 122: 923-30.
8. Sanyal AJ, Boyer T, Guadlupe G et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.
9. Singh V, Ghosh S, Singh B et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol 2012; 56: 1293-8.
10. Moreau R, Asselah T, Caudat B et al. Comparison of the Effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomized pilot study. Gut 2002; 50: 90-4.
11. Singh V, Kumar R, Nain CK et al. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis:a randomized controlled trial. J Gastroenterol Hepatol 2006; 21: 303-7.
12. Singh V, Dheerendra PC, Singh B et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol 2008; 103: 1399-405.
13. Appenrodt B, Wolf A, Grunhage F et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int 2008; 28: 1019-25.
14. Kalambokis G, Economou M, Fotopoulos A et al. The Effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites. Am J Gastroenterol 2005; 100: 879-85.
15. Kalambokis G, Fotopoulos A, Economou M et al. Effects of a 7 day treatment with midodrine in non azotemic cirrhotic patients with and without ascites. J Hepatol 2007; 46: 213-21.
16. Krag A, Moller S, Henriksen JH et al. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology 2007; 46: 1863-71.
17. Tandon P, Tsuyuki RT, Mitchell L et al. The Effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int 2009; 29: 169-74.
18. Singh V, Dhungana SP, Singh B et al. Role of long term midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. J Hepatol 2012; 56: 348-54.
19. Gines P, Quintero E, Arroyo V et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7: 122-8.
20. Moreau R, Lee SS, Hadengue A et al. Hemodynamic Effects of a clonidine-induced decrease in sympathetic tone in patients with cirrhosis. Hepatology 1987; 7: 149-54.
21. Roulot D, Moreau R, Gaudin C et al. Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis. Gastroenterology 1992; 102: 1209-18.
22. Lin HC, Tsai YT, Yang MC et al. Haemodynamic Effects of a combination of propranolol and clonidine in patients with post-hepatitic cirrhosis. J GastroenterolHepatol 1995; 10: 281-6.
23. Lenaerts A, Van Cauter J, Moukhaiber H et al. Treatment of refractory ascites with clonidine and spironolactone. Gastroenterol Clin Biol 1997; 21: 524-5.
24. Lenaerts A, Codden T, Van Cauter J et al. Interest of the association clonidine-spironolactone in cirrhotic patients with ascites and activation of sympathetic nervous system. Acta GastroenterolBelg 2002; 65: 1-5.
25. Lenaerts A, CoddenT, Meunier JC et al. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology 2006; 44: 844-9.
26. Yang YY, Lin HC, Lee WP et al. Association of the G-protein and á 2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the Effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial. Gut 2010; 59: 1545-53.
27. Arroyo V, Gines P, Gerbes AL et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
28. Moore KP, Wong F, Gines P et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38: 258-66.
29. Ruiz-Del-Arbol L, Monescillo A, Jimenez W et al. Paracentesis induced circulatory dysfunction: mechanism and Effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
31. Kupari M, Koskinen P. Systolic flow velocity profile in the left ventricular outflow tract in persons free of heart disease. Am J Cardiol 1993; 72: 1172-8.
32. Cardenas A, Gines P. Management of hyponatremia in cirrhosis. Ascites and renal dysfunction in liver disease, 2nd edn. Blackwell: Oxford, UK.
33. Angeli P, Volpin R, Piovan D et al. Acute Effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology 1998; 28: 937-43.
34. Lenaerts A, Codden T, Henry JP et al. Comparative pilot study of repeated large volume paracentesis vs the combination of clonidine-spironolactone in the treatment of cirrhosis-associated refractory ascites. Gastroenterol Clin Biol 2005; 29: 1137-42.
35. Albillos A, Banares P, Barrios C et al. Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamics and liver function Effects. Gastroenterology 1992; 102: 2185-6.
36. Angeli P, Volpin R, Gerunda G et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.